Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 29 Mar 2022 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 29 Mar 2022 |
| Genmab Announces the Nomination of a New Member of the Company’s Board of Directors | 14 Mar 2022 |
| Genmab A/S has published its Articles of Association | 9 Mar 2022 |
| Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma | 8 Mar 2022 |